Donation Helps Bring Novel Cancer Therapies to Lake Forest Hospital through Clinical Trials
Lake Forest Hospital April 10, 2015
“We wanted to help increase the number of treatment options available for cancer patients living in the northern suburbs,” said Guy Arvia. “It is very exciting to know that NMDTI will be able to provide exactly that here in Lake Forest through high quality clinical trials.”
NMDTI was established in downtown Chicago in 2013 with a focus on accelerating the translation of preclinical medical breakthroughs into better therapies for patients through support from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine and Northwestern Medicine Memorial Hospital.
“Bringing NMDTI to Lake Forest Hospital will allow us to offer patients in the suburbs new options for their cancer care that aren’t available anywhere else in the Chicago area,” said Valerie Nelson, MD, medical oncologist and director of the NMDTI clinic being created at Lake Forest Hospital. “Our Lake Forest patients can expect not only the best standard of care cancer treatments but also cutting edge therapies available through the clinical trials at our NMDTI clinic.”
The contribution from Guy and Janice Arvia is part of a $2 million philanthropic pledge by the Women's Board of Lake Forest Hospital in support of the campaign for the new Lake Forest Hospital campus. While the new hospital is scheduled to open in 2017, the Lake Forest Hospital NMDTI clinic is planning to start seeing patients this summer.
“With their gift, the Arvias have helped NMDTI further its mission of making novel therapies and clinical trials more widely available to cancer patients and advancing the translation of laboratory-based discoveries into effective therapeutic agents,” said Francis J. Giles, MD, deputy director of the Lurie Cancer Center and director of NMDTI.
“We will rapidly expand our tissue-agnostic studies to Lake Forest Hospital. These studies allow us to use a treatment developed to target the genetic characteristics of multiple cancer types that may seem different from each other on the surface, but actually share genetic targets and therefore therapeutic approaches. We are increasingly using new molecular tests to define those targets in our Northwestern Onco-SET program.”
To learn more about NMDTI and how to enroll in a developmental therapeutics clinical trial, please call 312-472-1234 or 855-82-NMDTI (855-826-6384).